STOCK TITAN

Ginkgo Bioworks Holdings, Inc. - $DNA STOCK NEWS

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: $DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.

Rhea-AI Summary
IdeeLab Biotechnology partners with Ginkgo Bioworks to enhance biological solutions for agriculture. IdeeLab will provide local strain discovery and manufacturing capabilities to Ginkgo's customers, enabling the development of next-generation products in Brazil's biologicals market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) to host Ferment conference on April 11, 2024, bringing together stakeholders in synthetic biology. Livestream available for public access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
conferences
-
Rhea-AI Summary
Prozomix and Ginkgo Bioworks announce a partnership to develop next-generation enzyme plates for API manufacturing. The collaboration aims to leverage Ginkgo's AI/ML models and Prozomix's enzyme libraries to create innovative biocatalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) acquires Modulus Therapeutics' cell therapy platform assets, enhancing cell therapy capabilities. Modulus' CAR and switch receptor libraries improve control and performance of immune cell-based therapies, potentially increasing safety and efficacy. Ginkgo aims to support customers in developing T-cell and NK-cell based CAR therapies for various diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) secures a $6 million contract from DARPA for the ICE program to develop novel biologically-sourced materials for ice control in extreme cold weather environments, potentially impacting commercial markets like optics, aviation, automobiles, and outdoor products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
none
-
Rhea-AI Summary
AQUA Cultured Foods partners with Ginkgo Bioworks to enhance fermentation technology for fish-free seafood products. AQUA's innovative process replicates the taste, texture, and appearance of fresh-caught seafood without using fish or animal inputs. The partnership aims to revolutionize alt-seafood production by leveraging Ginkgo's microbial expertise and analytics. AQUA's products offer a sustainable, healthier alternative to traditional seafood, free from contaminants and allergens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
partnership
Rhea-AI Summary
Imagindairy and Ginkgo Bioworks (NYSE: DNA) announce a partnership to produce non-whey dairy proteins for the food industry. The collaboration aims to leverage Ginkgo's Protein Expression Services and Imagindairy's expertise to develop sustainable animal-free dairy proteins funded by a joint grant from the Israel-U.S. BIRD Foundation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
-
Rhea-AI Summary
ProteoNic Biosciences partners with Ginkgo Bioworks (NYSE: DNA) to provide premium vector technology for biologics production, expanding into cell and gene therapy applications. This collaboration aims to drive innovation, enhance production capabilities, and reduce manufacturing costs in the biotech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
Ginkgo Bioworks Holdings, Inc. (DNA) reported $251 million in total revenue for 2023, with $139 million in Cell Engineering services revenue, representing 31% growth over 2022. The company added 78 new Cell Programs in 2023, showing 32% growth over the previous year. Ginkgo's year-end cash balance of nearly $950 million provides a strong financial runway. The company is focused on biopharma growth, global biosecurity, and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.13%
Tags
Rhea-AI Summary
bit.bio, a company coding human cells for novel cures, partners with Ginkgo Bioworks (NYSE: DNA) to integrate its ioCells™ portfolio of precision reprogrammed human cells into Ginkgo's platform ecosystem. This collaboration aims to provide physiologically-relevant human cell models at scale for Ginkgo's biopharma clients, enhancing disease biology insights and accelerating preclinical research and drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

DNA Rankings

DNA Stock Data

1.86B
1.12B
6.74%
83.82%
12.58%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.